Effects of free immunoglobulin light chains on viral myocarditis

Circulation Research

Volumn 106, Issue 9, 2010, Pages 1533-1540

  Matsumori, Akira ^a   Shimada, Miho ^a   Jie, Xiao ^a,b   Higuchi, Hirokazu ^a   Kormelink, Tom Groot ^c   Redegeld, Frank A ^c  

^a KYOTO UNIVERSITY   (Japan)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cardiomyopathy; Free immunoglobulin light chains; Heart failure; Myocarditis; Virus

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; INTERLEUKIN 10;

AMNION CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENCEPHALOMYOCARDITIS VIRUS; HEART PROTECTION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOGENESIS; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS CONCENTRATION; VIRUS MYOCARDITIS; VIRUS REPLICATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIVIRAL AGENTS; CARDIOVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; ENCEPHALOMYOCARDITIS VIRUS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MICE; MICE, INBRED DBA; MICROBIAL SENSITIVITY TESTS; MYOCARDITIS; SURVIVAL RATE; VIRUS REPLICATION;

EID: 77952422318     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.218438     Document Type: Article

References (39)

1. Elovaara I, Seppala I, Kinnunen E, Laaksovirta H. Increased occurrence of free immunoglobulin light chains in cerebrospinal fluid and serum in human immunodeficiency virus-1 infection. J Neuroimmunol. 1991;35: 65-77.
2. Gallo P, Piccinno MG, De Rossi A, Pagni S, Amadori A, Chieco-Bianchi L, Tavolato B. Free light chains of immunoglobulins in the cerebrospinal fluid of human immunodeficiency virus type 1-infected patients. J Neu-roimmunol. 1990;26:229-238.
3. Fagnart OC, Sindic CJ, Laterre C. Free kappa and lambda light chain levels in the cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. J Neuroimmunol. 1988;19:119-132.
4. Klein J, Horejs V. Immunology. Oxford, London, Malden: Blackwell Science Ltd; 1997.
5. Wahlstrom G, Pear WS, Steen ML, Szpirer J, Levan G, Klein G, Sumegi J. Localization of the rat immunoglobulin lambda light chain locus to chromosome 11. Immunogenetics. 1988;28:182-183.
6. Lai E, Wilson RK, Hood LE. Physical maps of the mouse and human immunoglobulin-like loci. Adv Immunol. 1989;46:1-59.
7. Scherer DC, Brockman JA, Bendall HH, Zhang GM, Ballard DW, Oltz EM. Corepression of RelA and c-rel inhibits immunoglobulin kappa gene transcription and rearrangement in precursor B lymphocytes. Immunity. 1996;5:563-574.
8. Igarashi H, Baba Y, Nagai Y, Jimi E, Ghosh S, Kincade PW. NF-kappaB is dispensable for normal lymphocyte development in bone marrow but required for protection of progenitors from TNFalpha. Int Immunol. 2006;18:653-659.
9. Cadera EJ, Wan F, Amin RH, Nolla H, Lenardo MJ, Schlissel MS. NF-kappaB activity marks cells engaged in receptor editing. J Exp Med. 2009;206:1803-1816.
10. Matsumori A. Molecular and immune mechanisms in the pathogenesis of cardiomyopathy-role of viruses, cytokines, and nitric oxide. Jpn Circ J. 1997;61:275-291.
11. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 1994;72:561-566.
12. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-241.
13. Matsumori A, Nunokawa Y, Yamaki A, Yamamoto K, Hwang MW, Miyamoto T, Hara M, Nishio R, Kitaura-Inenaga K, Ono K. Suppression of cytokines and nitric oxide production, and protection against lethal endotoxemia and viral myocarditis by a new NF-kappaB inhibitor. Eur J Heart Fail. 2004;6:137-144.
14. Matsumori A, Crumpacker CS, Abelmann WH. Prevention of viral myocarditis with recombinant human leukocyte interferon alpha A/D in a murine model. J Am Coll Cardiol. 1987;9:1320-1325.
15. Nishio R, Matsumori A, Shioi T, Ishida H, Sasayama S. Treatment of experimental viral myocarditis with interleukin-10. Circulation. 1999; 100:1102-1108.
16. Nakano A, Matsumori A, Kawamoto S, Tahara H, Yamato E, Sasayama S, Miyazaki JI. Cytokine gene therapy for myocarditis by in vivo elec-troporation. Hum Gene Ther. 2001;12:1289-1297.
17. Matsumori A, Kawai C. An animal model of congestive (dilated) cardio-myopathy: dilatation and hypertrophy of the heart in the chronic stage in DBA/2 mice with myocarditis caused by encephalomyocarditis virus. Circulation. 1982;66:355-360.
18. Matsumori A, Kawai C. An experimental model for congestive heart failure after encephalomyocarditis virus myocarditis in mice. Circulation. 1982;65:1230-1235.
19. Huang ZQ, Sanders PW. Localization of a single binding site for immu-noglobulin light chains on human Tamm-Horsfall glycoprotein. J Clin Invest. 1997;99:732-736.
20. Redegeld FA, van der Heijden MW, Kool M, Heijdra BM, Garssen J, Kraneveld AD, Van Loveren H, Roholl P, Saito T, Verbeek JS, Claassens J, Koster AS, Nijkamp FP. Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat Med. 2002;8:694-701.
21. Chen YY, Lin SY, Yeh YY, Hsiao HH, Wu CY, Chen ST, Wang AH. A modified protein precipitation procedure for efficient removal of albumin from serum. Electrophoresis. 2005;26:2117-2127.
22. Matsumori A, Wang H, Abelmann WH, Crumpacker CS. Treatment of viral myocarditis with ribavirin in an animal preparation. Circulation. 1985;71:834-839.
23. Kessler S, Kim KJ, Scher I. Surface membrane kappa and lambda light chain expression on spleen cells of neonatal and maturing normal and immune-defective CBA/NB mice: the kappa:lambda ratio is constant. J Immunol. 1981;127:1674-1678.
24. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509-516.
25. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246-253.
26. Hannam-Harris AC, Smith JL. Free immunoglobulin light chain synthesis by human foetal liver and cord blood lymphocytes. Immunology. 1981;43:417-423.
27. Shapiro AL, Scharff MD, Maizel JV, Uhr JW. Synthesis of excess light chains of gamma globulin by rabbit lymph node cells. Nature. 1966;211:243-245.
28. van der Heijden M, Kraneveld A, Redegeld F. Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. Eur J Pharmacol. 2006;533:319-326.
29. Thio M, Blokhuis BR, Nijkamp FP, Redegeld FA. Free immunoglobulin light chains: a novel target in the therapy of inflammatory diseases. Trends Pharmacol Sci. 2008;29:170-174.
30. DeCarli C, Menegus MA, Rudick RA. Free light chains in multiple sclerosis and infections of the CNS. Neurology. 1987;37:1334-1338.
31. Cooper A, Bluestone R. Free immunoglobulin light chains in connective tissue diseases. Ann Rheum Dis. 1968;27:537-543.
32. Terrier B, Sene D, Saadoun D, Ghillani-Dalbin P, Thibault V, Delluc A, Piette JC, Cacoub P. Serum-free light chain assessment in hepatitis C virus-related lymphoproliferative disorders. Ann Rheum Dis. 2009;68: 89-93.
33. Annunziata P, Battista A, Guazzi GC. Increase of predominantly k-type light chains in the CSF of a case of subacute sclerosing panencephalitis treated with interferon. Ital J Neurol Sci. 1985;6:215-219.
34. Udi N, Yehuda S. Intravenous immunoglobulin-indications and mechanisms in cardiovascular diseases. Autoimmun Rev. 2008;7:445-452.
35. Shoenfeld Y, Krause I. i.v.IG for autoimmune, fibrosis, and malignant conditions: our experience with 200 patients. J Clin Immunol. 2004;24:107-114.
36. Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ueland T, Lien E, Froland SS, Aukrust P. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103:220-225. (Pubitemid 32095406)
37. Maisch B, Hufnagel G, Kolsch S, Funck R, Richter A, Rupp H, Herzum M, Pankuweit S. Treatment of inflammatory dilated cardiomyopathy and (peri)myocarditis with immunosuppression and i.v. immunoglobulins. Herz. 2004;29:624-636.
38. Goland S, Czer LS, Siegel RJ, Tabak S, Jordan S, Luthringer D, Mirocha J, Coleman B, Kass RM, Trento A. Intravenous immunoglobulin treatment for acute fulminant inflammatory cardiomyopathy: series of six patients and review of literature. Can J Cardiol. 2008;24:571-574.
39. McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, Gass A, Janosko K, Tokarczyk T, Kessler P, Mann DL, Feldman AM. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103:2254-2259.